#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16956	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2641	792.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	2007	2007	T	1037	T,C,G	1032,3,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16956	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2641	792.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1741	1741	C	1075	C,A	1073,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16956	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2641	792.0	0	HET	.	.	.	C1269T	.	1269	1269	C	1826	1826	C	1034	C,T	827,206	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28470	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4012	884.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1885	1885	A	1190	A,T,G	1187,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28470	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4012	884.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2519	2519	C	954	C,T	953,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28470	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4012	884.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2593	2593	A	888	A,C	886,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28470	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4012	884.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	3145	3145	C	1056	C,T,G	1052,3,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	2630	folP	852	852	99.88	folP.l15.c4.ctg.1	1952	167.7	0	.	p	.	0	E151K	NONSYN	451	453	GAA	951	953	AAA	259;261;261	A,G,C;A;A	257,1,1;261;261	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	2630	folP	852	852	99.88	folP.l15.c4.ctg.1	1952	167.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1182	1184	AGC	245;245;246	A;G;C	245;245;246	folP.WHO_M_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5958	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3879	191.5	0	.	p	.	0	K261del	DEL	781	781	A	1427	1427	A	251	A,C	250,1	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5958	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3879	191.5	1	SNP	p	S91F	0	.	.	271	273	TCC	917	919	TCC	216;214;213	T;C;C	216;214;213	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5958	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3879	191.5	1	SNP	p	D95G	0	.	.	283	285	GAC	929	931	GAC	223;223;224	G,T;A;C,A	222,1;223;223,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5958	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3879	191.5	1	SNP	p	D95N	0	.	.	283	285	GAC	929	931	GAC	223;223;224	G,T;A;C,A	222,1;223;223,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	2382	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1796	165.6	1	SNP	p	G45D	0	.	.	133	135	GGC	678	680	GGC	289;290;290	G;G;C,A	289;290;289,1	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1318	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c30.ctg.1	1523	107.9	0	.	n	.	0	A197.	DEL	197	197	A	865	865	A	260	A	259	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5584	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3387	205.2	1	SNP	p	D86N	0	.	.	256	258	GAC	781	783	GAC	247;243;244	G;A,T;C	247;242,1;244	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5584	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3387	205.2	1	SNP	p	S87R	0	.	.	259	261	AGT	784	786	AGT	246;247;245	A,C;G;T,A	244,2;247;244,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5584	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3387	205.2	1	SNP	p	S87I	0	.	.	259	261	AGT	784	786	AGT	246;247;245	A,C;G;T,A	244,2;247;244,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5584	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3387	205.2	1	SNP	p	S87W	0	.	.	259	261	AGT	784	786	AGT	246;247;245	A,C;G;T,A	244,2;247;244,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5584	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3387	205.2	1	SNP	p	S88P	0	.	.	262	264	TCC	787	789	TCC	245;244;245	T;C;C,A	245;244;244,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4954	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3052	202.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1779	1781	GGC	250;248;247	G;G,T;C,G	250;247,1;246,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2831	208.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1457	1459	GCA	264;263;266	G,T;C,A;A,C	263,1;262,1;265,1	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2831	208.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1460	1462	ATC	265;265;262	A;T;C,A	265;265;261,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2831	208.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1472	1474	GTG	268;269;269	G;T;G,A	268;269;268,1	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2831	208.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1472	1474	GTG	268;269;269	G;T;G,A	268;269;268,1	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2831	208.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1976	1978	ACC	231;231;224	A;C;C	231;231;224	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2831	208.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2030	2032	GCG	231;232;231	G;C;G,T	231;232;229,2	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2831	208.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2030	2032	GCG	231;232;231	G;C;G,T	231;232;229,2	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2831	208.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2153	2155	GGC	254;257;255	G,T;G;C,A	253,1;257;254,1	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2831	208.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2162	2164	GGC	262;263;263	G,C;G,C;C,G	261,1;262,1;261,2	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4734	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2831	208.2	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2180	2182	CTG	272;272;273	C;T,G;G,C	272;271,1;272,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6802	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3619	234.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1891	1893	CCG	264;265;264	C,A;C;G	263,1;265;264	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	3042	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2316	163.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	865	865	C	227	C	227	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	226	90.71	porB1a.l6.c30.ctg.2	334	30.0	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	29;33;35	T;T;A	29;33;35	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	226	90.71	porB1a.l6.c30.ctg.2	334	30.0	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	60;60;60	C;A;T	60;60;60	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	226	90.71	porB1a.l6.c30.ctg.2	334	30.0	0	.	p	.	0	D274G	NONSYN	820	822	GAT	62	64	GGT	60;60;60	G;G;T	60;60;60	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	226	90.71	porB1a.l6.c30.ctg.2	334	30.0	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	60;60;60	T;A;C	60;60;60	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	226	90.71	porB1a.l6.c30.ctg.2	334	30.0	0	.	p	.	0	R307E	NONSYN	919	921	AGA	161	163	GAA	1;1;1	G;A;A	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	226	90.71	porB1a.l6.c30.ctg.2	334	30.0	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	226	90.71	porB1a.l6.c30.ctg.2	334	30.0	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	1;1;1	G;A;C	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	226	90.71	porB1a.l6.c30.ctg.2	334	30.0	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	1;1;1	A;T;C	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	226	90.71	porB1a.l6.c30.ctg.2	334	30.0	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	1;1;1	T;C;G	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	226	90.71	porB1a.l6.c30.ctg.2	334	30.0	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	1;1;1	G;C;C	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	226	90.71	porB1a.l6.c30.ctg.2	334	30.0	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	1;1;1	A;G;C	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	226	90.71	porB1a.l6.c30.ctg.2	334	30.0	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	316	porB1a	984	226	90.71	porB1a.l6.c30.ctg.2	334	30.0	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	2;2;2	G;T;T	2;2;2	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3250	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2112	191.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	714	716	GAA	302;299;301	G;A,G,C;A,C	302;297,1,1;300,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3250	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2112	191.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	1002	1004	GAT	291;293;296	G,A;A,C;T	290,1;292,1;296	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3250	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2112	191.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1125	1127	TCA	300;301;298	T;C,A;A	300;298,1;297	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3250	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2112	191.9	0	.	p	.	0	D212N	NONSYN	634	636	GAT	1236	1238	AAT	265;268;267	A;A;T,A,G	265;268;264,2,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3250	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2112	191.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1254	1256	GTC	264;260;262	G;T,G,C;C,G,T	264;258,1,1;260,1,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3250	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2112	191.9	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1266	1268	TCT	265;265;267	T;C;T	265;265;267	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3250	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2112	191.9	0	.	p	.	0	S295G	NONSYN	883	885	AGT	1485	1487	GGT	232;232;233	G,A;G;T	231,1;232;233	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3250	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2112	191.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1584	1586	GCA	265;266;267	G;C,A;A,C	265;263,3;266,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3250	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2112	191.9	1	SNP	p	G120K	1	.	.	358	360	AAG	960	962	AAG	295;296;295	A,C;A;G,A	293,2;296;294,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3250	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2112	191.9	1	SNP	p	A121D	1	.	.	361	363	GAC	963	965	GAC	294;291;292	G;A;C,A	294;291;291,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3250	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	2112	191.9	1	SNP	p	D121N	0	.	.	361	363	GAC	963	965	GAC	294;291;292	G;A;C,A	294;291;291,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	11392	rpoB	4179	4179	99.95	rpoB.l15.c4.ctg.1	5431	261.6	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2275	2277	AAT	266;267;273	A,C;A;T	265,1;267;273	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	11392	rpoB	4179	4179	99.95	rpoB.l15.c4.ctg.1	5431	261.6	0	.	p	.	0	A1019V	NONSYN	3055	3057	GCC	3673	3675	GTC	327;328;330	G;T,G;C,A	327;327,1;329,1	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1650	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1523	135.2	1	SNP	p	V57M	1	.	.	169	171	ATG	792	794	ATG	261;265;265	A;T;G	261;265;265	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
